Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Évaluation des effets des interventions prébiotiques et en fibres sur le sommeil, le microbiote intestinal, la cognition et le stress.

9 novembre 2026 mis à jour par: Northumbria University

Evaluating the Effects of Nutritional Interventions on Sleep, the Gut Microbiome, Cognition, and Stress

This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day period. At baseline and following 28 days of consumption, sleep quality, gut microbiome profiles, cognitive performance, and mood will be assessed. Sleep outcome measures will also be assessed throughout the supplementation period to monitor the time course of any observed changes. A final data set of at least 66 participants is expected.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Description détaillée

This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day period. At baseline and following 28 days of consumption, sleep quality, gut microbiome profiles, cognitive performance, and mood will be assessed. Sleep outcome measures will also be assessed throughout the supplementation period to monitor the time course of any observed changes. A final data set of at least 66 participants is expected.

Interested participants will initially be scheduled to complete a screening telephone call with the researcher. Here, electronic informed consent will first be provided by the participant, by accessing a pre-emailed link to the Qualtrics survey platform, to an account which is hosted by Northumbria University. Once consent is obtained, the participant will confirm that they do not meet any of the study exclusion criteria, and will complete the SDS-CL checklist with the researcher, over the phone. If any clinical thresholds are met, participants will be invited to a separate clinical interview (again via phonecall) with Professor Jason Ellis, employing the International Classification of Sleep Disorders (ICSD-3) criteria, to determine elligibility.

If participants progress to enrolment, they will be invited to attend a lab-based training/screening session (protocol day -7) at Northumbria University. Here, hard and wet-signed (by both the participant and the researcher) consent forms will be completed and stored on site. Participants will then be familiarised with the study protocol and procedures. Participants will also be trained on the cognitive tasks. During the following 7 nights (Protocol days -7 to -1), participants will monitor their sleep and complete the daily Sleep Diary each morning. During this week, they will also drop off their pre-dose baseline stool sample at a remote drop-off location at Northumbria University.

Seven days following the lab-based screening visit (Supplement day 1, Protocol day 0), participants will attend the laboratory for their acute visit. Here, a pre-dose baseline sample of saliva and a single blood sample will be taken (for Alpha Amylase, Cortisol, Serotonin and Melatonin), and Blood Pressure, Heart Rate, Body Mass Index, and Waist-to-Hip Ratio will be measured. Participants will complete the Intake24 dietary assessment, and gastrointestinal symptoms questionnaires, as well as the Pittsburgh Sleep Quality Index (PSQI), State-Trait Anxiety Inventory (STAI), and Depression, Anxiety and Stress Scale - 21 Items (DASS-21). The cognitive task battery will additionally be completed.

After completing these measures, participants will receive instructions on the next phase of the trial. From that night, participants will consume their first dose of the investigational supplement (noting the time in their treatyment diary) 4 hours before their normal bed-time. They will monitor their sleep overnight. The following morning (supplementation day 2, protocol day 1), participants will complete their Sleep Diary. Participants will follow this procedure for the following 27 days. At some point during Protocol (Days 12-18), participants will return to Northumbria University to drop-off their interim stool sample.

On Protocol day 28, participants will return to the lab for the chronic testing visit. All of the outcome measures assessed during the acute lab visit (Protocol day 0) will be repeated here. At the end of the session, participants will be debriefed, and their participation payment arranged. At some point during Protocol (Days 27-33) participants will return to Northumbria University to drop-off their chronic stool sample.

Type d'étude

Interventionnel

Inscription (Réel)

69

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Newcastle upon Tyne, Royaume-Uni
        • Northumbria University- Northumbria Sleep center and NUTRAN

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

25 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

INCLUSION CRITERIA

  • Participants must self-assess themselves as being in good health.
  • Aged 25 to 60 years at the time of randomisation
  • Fluent in English
  • Identify as a 'poor sleeper' as defined subjectively (i.e. poor sleep quality, unrefreshing sleep) and a total score of >5 on the Pittsburgh Sleep Quality Index (PSQI).

EXCLUSION CRITERIA

  • Member of own household currently participating in this trial
  • Evidence of current or recent sleep disorders (e.g. sleep apnoea, insomnia, circadian rhythm disorders), taking any medication which exerts sedative effects, affects the CNS and/or sleep, or be currently unwell with any illness that affects sleep (i.e. disorders of the CNS). An initial screening for sleep disorders will be conducted using the Sleep Disorders Symptom Checklist-25 (SDS-CL; Klingman et al., 2017). If a participant reports positively to any of the 25 questions in terms of being affected for three nights per week, or more, this will be followed up using a clinical interview according to the International Classification of Sleep Disorders (ICSD-3) to exclude on the basis of a sleep disorder
  • History of seizures or epilepsy
  • Shift working or have a history of shift work within the previous six months
  • Currently, or within the previous 8 weeks, consuming any nutritional supplements.
  • Participation in any other intervention research trials
  • Sleeping at a location other than their usual residence more than two nights per week during participation
  • Travel across multiple time zones within the last three months or have planned travel across multiple time zones during the study
  • Current or recent mood disturbances or Axis I disorders (descriptions will be given)
  • Current misuse of alcohol and/or drugs
  • Current smoker
  • Recent (within the last 12 weeks) infection and/or use of antibiotic medication
  • Pregnant, seeking to become pregnant or lactating
  • Those using (including within the last 2 weeks) proton-pump inhibitors

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Arm 1

Participants will be randomly allocated to consume investigational supplement (1 of 2 proprietary 'active' compositions) for 28 days.

A proprietary orally administered dietary supplement consisting of standardized ingredients.

Expérimental: Arm 2

Participants will be randomly allocated to consume investigational supplement (1 of 2 proprietary 'active' compositions) for 28 days.

A proprietary orally administered dietary supplement consisting of standardized ingredients.

Comparateur placebo: Control

Participants will be randomly allocated to consume control supplement for 28 days.

Flavored vehicle

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Sleep Efficiency (SE)
Délai: Change from Baseline to end of supplementation period at 28 days

Sleep efficiency (SE), commonly defined as the ratio of total sleep time (TST) to time in bed (TIB), will be reported as a percentage of time in bed.

Change from Baseline to end of supplementation period at 28 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Actigraphy - Sleep onset latency
Délai: Change from baseline following 28 days of supplement consumption

recorded minutes taken from intention to sleep to sleep initiation

Change from baseline following 28 days of supplement consumption
Actigraphy - Sleep efficiency
Délai: Change from baseline following 28 days of supplement consumption

ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed (percentage)

Change from baseline following 28 days of supplement consumption
Actigraphy - Number of awakenings
Délai: Change from baseline following 28 days of supplement consumption

recorded number of awakenings during entire sleep period

Change from baseline following 28 days of supplement consumption
Actigraphy - Wake after sleep onset (WASO)
Délai: Change from baseline following 28 days of supplement consumption

recorded minutes awake during the entire sleep period following sleep onset

Change from baseline following 28 days of supplement consumption
COMPASS global performance measures
Délai: Change from baseline following 28 days of supplement consumption

Speed of performance, and accuracy of performance measured by Computerised Mental Performance Assessment System (COMPASS, Northumbria University)

Change from baseline following 28 days of supplement consumption
Pittsburgh Sleep Quality Index (PSQI)
Délai: Change from baseline following 28 days of supplement consumption

Pittsburgh Sleep Quality Index (PSQI): Total Score. The PSQI is a validated self-rating instrument assessing aspects of sleep quality.Minimum score 0 (better); maximum score 21 (worse) < or = 5 associated with good sleep quality; > 5 associated with poor sleep quality.

Change from baseline following 28 days of supplement consumption
Depression, Anxiety and Stress Scale - 21 Items (DASS-21)
Délai: Change from baseline following 28 days of supplement consumption

A 21-item measure of mood over the previous week (each item is rated on scale from 0-3). Scoring creates 3 component scores: depression, anxiety and stress (each on a scale of 0-21) with higher scores indicating higher symptomology. Cut-off scores, according to each set of symptoms, are available (normal, mild, moderate, severe and extremely severe) or total scores can be derived by multiplying the sum of all three component scores by 2.

Change from baseline following 28 days of supplement consumption
State-Trait Anxiety Inventory (STAI)
Délai: Change from baseline following 28 days of supplement consumption

A 40-item measure of current and general anxiety levels. Each item is rated on a scale from 1-4. Scoring creates two components: state anxiety (20 items) and trait anxiety (20 items), with a range for each between 20-80. Following transformation through reversed coding, higher scores indicate higher levels of anxiety

Change from baseline following 28 days of supplement consumption
Actigraphy - Total sleep time
Délai: Change from baseline following 28 days of supplement consumption

recorded minutes asleep over entire sleep period

Change from baseline following 28 days of supplement consumption
Sleep Diary - Total sleep time
Délai: Change from baseline following 28 days of supplement consumption

recorded minutes asleep over entire sleep period

Change from baseline following 28 days of supplement consumption
Sleep Diary - Sleep onset latency
Délai: Change from baseline following 28 days of supplement consumption

logged minutes taken from intention to sleep to sleep initiation

Change from baseline following 28 days of supplement consumption
Sleep Diary - Sleep efficiency
Délai: Change from baseline following 28 days of supplement consumption

ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed (percentage)

Change from baseline following 28 days of supplement consumption
Sleep Diary - Number of awakenings
Délai: Change from baseline following 28 days of supplement consumption

logged number of awakenings during entire sleep period

Change from baseline following 28 days of supplement consumption
Sleep Diary - Wake after sleep onset (WASO)
Délai: Change from baseline following 28 days of supplement consumption

logged minutes awake during the entire sleep period following sleep onset

Change from baseline following 28 days of supplement consumption

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Professor Jason Ellis, PhD, Northumbria University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 avril 2026

Achèvement primaire (Estimé)

1 décembre 2026

Achèvement de l'étude (Estimé)

1 avril 2027

Dates d'inscription aux études

Première soumission

19 janvier 2026

Première soumission répondant aux critères de contrôle qualité

19 janvier 2026

Première publication (Réel)

27 janvier 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 février 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 000000

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .